Cogent Biosciences Inc reports results for the quarter ended September 30 - Earnings Summary

Cogent Biosciences

12/11/2024 15:28

* Cogent Biosciences Inc  COGT.OQ  reported a quarterly
adjusted
loss of 64 cents​​ per share for the quarter ended September 30,
identical to the same quarter last year.  The mean expectation
of eleven analysts for the quarter was for a loss of 57 cents
per share. Wall Street expected results to range from -67 cents
to -44 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cogent Biosciences Inc's reported EPS for the quarter was
a loss
of 64 cents​.
    * The company reported a quarterly loss of $70.63 million.
    * Cogent Biosciences Inc shares had fallen by 3.7% this
quarter and gained 76.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 0.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 9 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cogent
Biosciences Inc is $16.00 
This summary was machine generated from LSEG data November 12 at
03:28 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2024      -0.57          -0.64          Missed
 Jun. 30 2024      -0.56          -0.59          Missed
 Mar. 31 2024      -0.52          -0.62          Missed
 Dec. 31 2023      -0.56          -0.63          Missed